

ϕ macomics



Company Overview

Macomics Ltd is a biotechnology company founded in 2020 as a University of Edinburgh spin-out by Professor Jeffery Pollard and Dr. Luca Cassetta, specialising in macrophage biology and developing precision medicines to modulate tumour-associated macrophages and enhance immune responses against cancer and other diseases. The company positions itself at the intersection of macrophage biology and targeted immunotherapy.

Key Challenges Addressed

Tumour-associated macrophages are immune cells within the tumour micro-environment that support tumour growth and suppress the body's natural defences, reducing the effectiveness of some cancer treatments. Macomics has developed its ENIGMAC™ platform to reprogramme or target these macrophages and restore anti-tumour immunity. The company is also applying this platform to inflammatory and fibrotic diseases in which macrophages drive pathology; identifying disease-relevant macrophages and translating them into safe, drug-like molecules.

Role of Roslin Innovation Centre

Macomics moved into dedicated laboratories at Roslin Innovation Centre in January 2023, gaining a larger, purpose-built base to support its expanding research & development operations and headcount. Being located in a recognised life-science innovation hub provides access to academic collaborators, core facilities, entrepreneurial support, and talent pipelines. The versatility and flexibility of Roslin Innovation Centre's laboratory and office space accommodate its increasing scientific team and research activity, strengthening Macomics' technical capacity and has provided room to develop and launch new projects.



Within months after establishing its base at Roslin Innovation Centre, Macomics secured a major global drug discovery collaboration focused on macrophage-targeting antibodies. Access to Roslin Innovation Centre's specialist infrastructure, networks, and innovation environment was instrumental to enabling this collaboration, which has significantly strengthened the company's resources, profile, and future commercial ambitions.

Macomics has used the supportive, connected ecosystem of Roslin Innovation Centre to accelerate macrophage science, originating from the University of Edinburgh, into a robust discovery platform and an expanding therapeutic pipeline. Supported by its Roslin Innovation Centre-based team, close university partnerships, and expanding international collaborations, Macomics showcases how Roslin Innovation Centre's environment can foster pioneering science and turn it into a commercially successful therapeutics company.